W. L. Gore & Associates, Inc.

GORE PROPATENVascular Graft

SHARE

Addressing the problem of thrombus formation on the luminal surface of a vascular graft is a challenge faced by all vascular surgeons. The GORE PROPATEN Vascular Graft is specifically designed for those vascular procedures in which the risk of acute graft thrombotic failure is of clinical concern.

Most popular related searches

The GORE PROPATEN Vascular Graft harnesses the anticoagulant properties of heparin directly at the luminal surface of the graft. The proprietary end-point attachment mechanism, the CBAS Heparin Surface, serves to anchor heparin molecules to the luminal surface while still maintaining heparin`s intrinsic bioactive properties. The result: a thromboresistant bioactive graft surface that retains its bioactive properties.1

The GORE PROPATEN Vascular Graft has demonstrated improved thromboresistance and patency compared to standard ePTFE grafts in pre-clinical in vivo tests. A randomized, multi-center clinical study has shown promising results.2 The thromboresistant surface technology employed on the GORE PROPATEN Vascular Graft is designed to maintain bioactivity, thus increasing the potential for performance improvement and increased patency*.